+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 3 Actively Recruiting clinical trials

R

Actively Recruiting

Researchers are evaluating the real-world effectiveness of angiotensin receptor-neprilysin inhibitor ARNi therapy compared to antihypertensive monotherapy in lowering blood pressure among adults with hypertension in the United Arab Emirates. The study focuses on patients diagnosed with hypertension and aims to see how these treatments impact blood pressure control in everyday clinical settings. The study includes two groups one group starts or switches to ARNi treatment sacubitrilvalsartan, and the other begins antihypertensive monotherapy with either an ACE inhibitor, an ARB, or a calcium channel blocker. Patients will be observed as they receive these therapies according to their physicians direction. Participants will have their blood pressure measured at the start and during follow-up visits, with primary measurement focused on the change in mean sitting systolic blood pressure from baseline to week 4. Additional measures include diastolic blood pressure, pulse pressure, and the proportion of patients reaching target blood pressure at weeks 4 and 12. The study will continue until August 2027, with assessments occurring at these defined timepoints to monitor treatment effects and safety.

Age: 18Years - 99YearsAll Genders
4 locations
I

Actively Recruiting

Researchers are evaluating whether a pharmacist-led educational program can reduce the inappropriate use of proton pump inhibitors PPIs among adults aged 18 years and older with potentially unnecessary PPI prescriptions in Ras Al Khaimah. The study aims to see if this intervention can lower PPI use, improve patients quality of life, and reduce healthcare costs by comparing the intervention group to those receiving usual care. The study is interventional and involves education for both patients and physicians to promote evidence-based deprescribing practices. The study has two groups one receives a pharmacist-led educational intervention including brochures, videos, decision aids, and deprescribing algorithms aimed at encouraging appropriate PPI use. The other group continues with standard care without any pharmacist intervention during the six-month period. Physicians in the intervention group also receive educational materials and guidance to support deprescribing. After six months, educational materials will be offered to the control group. Participants will be followed for six months to track changes in PPI use, symptoms related to gastroesophageal reflux disease, quality of life, medication counts, potential adverse effects, attitudes toward deprescribing, and healthcare costs. Assessments include questionnaires such as the Gastroesophageal Reflux Disease Impact Scale and EuroQol 5-Dimension 5-Level survey. Researchers will monitor if patients stop or reduce PPI doses and evaluate cost-effectiveness and quality-adjusted life years gained over the study period.

Age: 18Years +All GendersPhase Not Applicable
1 location
S

Actively Recruiting

Researchers are studying the effects of dupilumab treatment on mental health, specifically anxiety and depression symptoms, as well as quality of life in patients with moderate-to-severe atopic dermatitis AD. The study focuses on patients already receiving dupilumab, aiming to observe how this treatment impacts their psychological well-being and life quality over time. Participants will be observed during a 6-month period while continuing their dupilumab therapy as prescribed by their doctors in real-world clinical settings. The study does not administer any treatments but monitors patients who start dupilumab within 30 days before enrollment. The enrollment period for the study will last about 9 months. Throughout the study, participants will complete assessments measuring anxiety and depression levels using the Hospital Anxiety and Depression Scale HADS and quality of life via tools like the Patient-Oriented Eczema Measure POEM and Dermatology Life Quality Index DLQI. Researchers will evaluate changes from baseline to week 24 in these scores and monitor professional and psychological impacts. The study aims to better understand the mental health outcomes of patients receiving dupilumab over six months.

Age: 12Years +All Genders
7 locations